Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
RCUS
#1597
Arcus Biosciences, Inc.
20.3
8
+4.57%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+4.57%
Monthly Change
-12.53%
6 month change
+92.26%
Year Change
+96.53%
Previous Close
19.4
9
Open
20.1
5
Bid
Ask
Low
20.0
7
High
20.4
4
Volume
601
Markets
US Stock Market
Healthcare
RCUS
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Dividends per share
—
—
—
—
—
—
—
Dividend yield %
—
—
—
—
—
—
—
Payout ratio %
—
—
—
—
—
—
—
News
Arcus Biosciences, Inc. 2025 Q4 - Results - Earnings Call Presentation (NYSE:RCUS) 2026-02-27
RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Alkermes Down Despite Q4 Earnings Beat, Announces Leadership Change
Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
Arcus Biosciences, Inc. (RCUS) Q4 2025 Earnings Call Transcript
Arcus 2025 presentation: casdatifan data strengthens, I&I pipeline emerges
Arcus Biosciences earnings beat by $0.21, revenue fell short of estimates
Arcus Biosciences in spotlight: Kidney drug trial results at stake
AMD, IBM among market cap stock movers on Tuesday
Arcus reports casdatifan trial data in kidney cancer patients